Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Trials
Collaboration
Funding
Research and Development: Page 2
Ginkgo Bioworks launches technology network
By
Matt Limb
Ginkgo Bioworks has launched a new technology network with 25 partners, pledging to improve customersâ research and development outcomes.
March 6, 2024
New class of broad-spectrum antivirals could be first line of pandemic defense: Study
By
Nick Paul Taylor
Targeting a cellular pathway has inhibited SARS-CoV-2 and other RNA viruses in preclinical tests, pointing to a potential new class of first-line antivirals with broad effectiveness against emerging pathogens.
March 5, 2024
AMDI receives $5.2M in RADx Tech funding for PCR viral testing system
By
LabPulse.com staff writers
Autonomous Medical Devices Incorporated (AMDI) has received a U.S. National Institutes of Health (NIH) RADx Tech award of up to $5.2 million to finalize its rapid point-of-care viral testing system.
March 4, 2024
Novartis presents first results of SMART spinal muscular atrophy study
By
LabPulse.com staff writers
Company presents new data from a clinical study, called the SMART study, of its gene therapy in previously treated patients and a broader patient population.
March 5, 2024
BioMĂ©rieux, FDA to collaborate on combating food-borne pathogens
By
LabPulse.com staff writers
BioMĂ©rieux has entered into a strategic research collaboration with the U.S. Food and Drug Administration (FDA) to develop technologies to improve the detection and characterization of food-borne pathogens.
March 1, 2024
Alzheimerâs study results show correlation between blood-based biomarkers and amyloid plaques
By
LabPulse.com staff writers
The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).
March 1, 2024
MD Anderson Cancer Center, C-Biomex collaborate on CA9-targeting radioligand
By
Matt Limb
The University of Texas MD Anderson Cancer Center has signed an agreement with South Korean company C-Biomex to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
February 29, 2024
National Cancer Institute launches network to evaluate cancer screening technologies
By
LabPulse.com staff writers
In support of the Biden-Harris administrationâs Cancer Moonshot initiative, the U.S. National Institutes of Health has launched the Cancer Screening Research Network, a clinical trial network for evaluating emerging cancer screening technologies.
February 22, 2024
âRemarkableâ results in lupus patients spark speculation CAR-T may cure autoimmunity
By
Nick Paul Taylor
The generation of âremarkableâ results in lupus patients has sparked speculation about the potential for chimeric antigen receptor T-cell (CAR-T cell) therapy to cure autoimmune diseases.
February 23, 2024
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test
By
LabPulse.com staff writers
CARB-X will award up to $1.8 million to biotech firm Visby Medical to develop a portable rapid polymerase chain reaction test to detect
Neisseria gonorrhoeae
, the pathogen that causes gonorrhea, including its susceptibility to ciprofloxacin.
February 8, 2024
U.K. trial for mRNA-based cancer therapy begins
By
Matt Limb
Cancer patients in the U.K. are receiving an experimental mRNA therapy designed to help their bodies recognize and fight cancer cells.
February 7, 2024
BioMĂ©rieux, UPitt in new three-year agreement
By
LabPulse.com staff writers
BioMĂ©rieux and the University of Pittsburgh have entered into a three-year diagnostics research agreement, the university announced in Pittwire.
February 2, 2024
Previous Page
Page 2 of 39
Next Page